Gary G Zhao, MD
Hematology/Oncology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
24 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Zhao’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A83349 · Current
Licensed to practise in California · since 2003 · expires 2028-09-30 · Shanghai Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$50,796
Medicare paid this office $50,796 for 429 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 201 | $20,865 | $79 |
| Short return visit (20+ min) | 202 | $13,220 | $50 |
| Long return visit (40+ min) | 30 | $4,039 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $3,059 | $71 |
| New patient visit (45+ min) | 31 | $2,923 | $94 |
See all 9 services
| Return visit (30+ min) | 201 | $20,865 | $79 |
| Short return visit (20+ min) | 202 | $13,220 | $50 |
| Long return visit (40+ min) | 30 | $4,039 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $3,059 | $71 |
| New patient visit (45+ min) | 31 | $2,923 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,699 | $117 |
| Telephone medical discussion with physician, 5-10 minutes | 52 | $1,230 | $22 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $996 | $55 |
| New patient visit (30+ min) | 16 | $839 | $52 |
Who their Medicare patients are
429 Original Medicare patients in 2024. Average age 73 · Under 65 12% · 85 and older 11% · Women 50% · Also on Medicaid 79% · Health risk score 2.05. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 51% · Diabetes 47% · Chronic kidney disease 27% · Coronary heart disease 22% · Heart failure 22% · Depression 17% · COPD 16% · Atrial fibrillation 16% · Stroke 8% · Dementia 7%.
The office billed $475,258, Medicare allowed $73,597 and paid $50,796; for 764 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 429 | 764 | 73 | 2.05 | $475,258 | $50,796 |
| 2023 | 390 | 815 | 72 | 1.83 | $509,902 | $55,970 |
| 2022 | 224 | 466 | 71 | 1.77 | $250,102 | $31,883 |
| 2021 | 178 | 411 | 71 | 2.24 | $172,700 | $28,848 |
| 2020 | 159 | 398 | 69 | 2.19 | $176,081 | $23,338 |
| 2019 | 38 | 49 | 69 | 1.73 | $32,593 | $3,692 |
| 2018 | 62 | 93 | 72 | 2.27 | $53,988 | $5,254 |
| 2017 | 207 | 478 | 69 | 2.19 | $269,047 | $31,106 |
| 2016 | 157 | 346 | 68 | 2.09 | $127,745 | $21,351 |
| 2015 | 146 | 332 | 68 | 1.86 | $110,294 | $21,579 |
| 2014 | 144 | 401 | 68 | 1.76 | $116,152 | $27,795 |
| 2013 | 93 | 193 | 68 | 1.70 | $56,683 | $16,070 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 171 | $18,098 | $72 |
| Short return visit (20+ min) | 224 | $17,020 | $49 |
| Long return visit (40+ min) | 34 | $7,900 | $118 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,976 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $3,922 | $74 |
| New patient visit (45+ min) | 18 | $2,176 | $121 |
| New patient visit (30+ min) | 12 | $833 | $69 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $422 | $30 |
2022: 8 services
| Return visit (30+ min) | 87 | $9,941 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $5,890 | $103 |
| Short return visit (20+ min) | 58 | $3,346 | $57 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 33 | $3,287 | $100 |
| Telephone medical discussion with physician, 5-10 minutes | 77 | $2,828 | $24 |
| Long return visit (40+ min) | 14 | $2,425 | $135 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,095 | $78 |
| Short return visit | 12 | $364 | $30 |
2021: 7 services
| Telephone medical discussion with physician, 21-30 minutes | 73 | $8,323 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $7,206 | $118 |
| Telephone medical discussion with physician, 5-10 minutes | 97 | $4,803 | $32 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $2,188 | $104 |
| Telephone medical discussion with physician, 11-20 minutes | 30 | $1,888 | $57 |
| Return visit (30+ min) | 16 | $1,561 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,526 | $80 |
2020: 6 services
| Telephone medical discussion with physician, 11-20 minutes | 94 | $7,420 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $4,830 | $110 |
| Telephone medical discussion with physician, 21-30 minutes | 31 | $2,629 | $71 |
| Return visit (30+ min) | 47 | $2,340 | $42 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $2,020 | $106 |
| Telephone medical discussion with physician, 5-10 minutes | 40 | $1,121 | $24 |
2019: 1 service
| Return visit (30+ min) | 27 | $1,873 | $67 |
2018: 2 services
| Return visit (30+ min) | 29 | $1,298 | $45 |
| Short return visit (20+ min) | 14 | $224 | $16 |
2017: 8 services
| Return visit (30+ min) | 127 | $15,184 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $5,078 | $91 |
| Short return visit (20+ min) | 56 | $2,500 | $36 |
| Long return visit (40+ min) | 18 | $1,836 | $97 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,741 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,634 | $63 |
| New patient visit (45+ min) | 17 | $1,631 | $96 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,479 | $87 |
2016: 6 services
| Return visit (30+ min) | 110 | $12,140 | $61 |
| Short return visit (20+ min) | 52 | $2,675 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,897 | $90 |
| Long return visit (40+ min) | 19 | $1,575 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,197 | $63 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $948 | $86 |
2015: 4 services
| Return visit (30+ min) | 95 | $12,056 | $59 |
| Long return visit (40+ min) | 60 | $5,369 | $87 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,041 | $87 |
| Short return visit (20+ min) | 15 | $527 | $33 |
2014: 4 services
| Return visit (30+ min) | 100 | $15,950 | $63 |
| Long return visit (40+ min) | 42 | $4,365 | $97 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,678 | $122 |
| Short return visit (20+ min) | 23 | $1,023 | $39 |
2013: 2 services
| Long return visit (40+ min) | 56 | $8,171 | $91 |
| Return visit (30+ min) | 45 | $4,406 | $64 |
Medicaid work
$28,542 in 2024
Medicaid paid $28,542 for 4,659 billed services this clinician did in 2024, up to 169 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 921 | $13,488 |
| Short return visit (20+ min) | 983 | $10,879 |
| Long return visit (40+ min) | 122 | $2,656 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 29 | $673 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 41 | $516 |
| New patient visit (30+ min) | 17 | $228 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 18 | $85 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 12 | $18 |
| Pain severity quantified; no pain present (COA) (ONC) | 23 | $0 |
| Medication list documented in medical record (COA) | 941 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 226 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 350 | $0 |
| 2024 | 4,659 | 16 | 169 | $28,542 |
| 2023 | 2,590 | 10 | 130 | $16,479 |
| 2022 | 801 | 5 | 97 | $6,884 |
| 2021 | 654 | 5 | 54 | $7,611 |
| 2020 | 562 | 5 | 120 | $5,192 |
| 2019 | 1,203 | 8 | 116 | $8,339 |
| 2018 | 1,471 | 8 | 91 | $11,727 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 898 | $6,439 |
| Short return visit (20+ min) | 1,188 | $5,096 |
| Long return visit (40+ min) | 201 | $2,832 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 106 | $1,458 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 16 | $373 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 14 | $267 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 15 | $14 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 105 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 14 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 33 | $0 |
2022
| Return visit (30+ min) | 518 | $5,380 |
| Short return visit (20+ min) | 210 | $1,089 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 22 | $206 |
| Short return visit | 37 | $139 |
| Long return visit (40+ min) | 14 | $70 |
2021
| Return visit (30+ min) | 464 | $5,525 |
| Short return visit (20+ min) | 99 | $985 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $420 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 43 | $370 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 13 | $310 |
2020
| Return visit (30+ min) | 315 | $2,424 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 80 | $1,079 |
| Short return visit (20+ min) | 132 | $921 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 18 | $618 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 17 | $150 |
2019
| Return visit (30+ min) | 891 | $4,922 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 48 | $1,434 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 122 | $1,050 |
| Service | 15 | $512 |
| HEPATIC FUNCTION PANEL | 84 | $279 |
| ELECTROLYTE PANEL | 14 | $111 |
| Blood glucose (sugar) level | 15 | $26 |
| Creatinine; blood | 14 | $4 |
2018
| Return visit (30+ min) | 794 | $5,158 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 233 | $2,055 |
| Service | 48 | $1,637 |
| Short return visit (20+ min) | 232 | $1,340 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 61 | $808 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 13 | $305 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 24 | $251 |
| HEPATIC FUNCTION PANEL | 66 | $173 |
Drugs they prescribed that Part D paid
$2,987,000
Pharmacies billed $2,987,000 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
507 generic and 228 brand-name prescriptions · $2,987,000 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 66 | $1,031,970 | $15,636 |
| Xtandi | 27 | $344,896 | $12,774 |
| Imbruvica | 17 | $196,955 | $11,586 |
| Gilotrif | 14 | $152,976 | $10,927 |
| Abiraterone Acetate | 113 | $123,138 | $1,090 |
See all 16 drugs
| Tagrisso | 66 | $1,031,970 | $15,636 |
| Xtandi | 27 | $344,896 | $12,774 |
| Imbruvica | 17 | $196,955 | $11,586 |
| Gilotrif | 14 | $152,976 | $10,927 |
| Abiraterone Acetate | 113 | $123,138 | $1,090 |
| Imatinib Mesylate | 24 | $33,646 | $1,402 |
| Posaconazole | 14 | $14,195 | $1,014 |
| Prednisone | 121 | $618 | $5 |
| Bicalutamide | 39 | $508 | $13 |
| Hydroxyurea | 26 | $468 | $18 |
| Prochlorperazine Maleate | 20 | $297 | $15 |
| Loperamide | 16 | $110 | $7 |
| Omeprazole | 20 | $76 | $4 |
| Alendronate | 12 | $71 | $6 |
| Ondansetron | 23 | $66 | $3 |
| Gabapentin | 13 | $37 | $3 |
Year by year
| 2024 | 735 | 92 | None | 31% | $2,987,000 |
| 2023 | 681 | 76 | 2% (11) | 28% | $2,479,052 |
| 2022 | 613 | 78 | 4% (23) | 34% | $2,364,991 |
| 2021 | 556 | 73 | 2% (13) | 38% | $2,348,355 |
| 2020 | 555 | 81 | 4% (20) | 37% | $2,217,369 |
| 2019 | 601 | 91 | 3% (20) | 29% | $1,697,371 |
| 2018 | 531 | 78 | 5% (28) | 35% | $1,957,168 |
| 2017 | 574 | 83 | 4% (23) | 36% | $1,922,985 |
| 2016 | 609 | 80 | 4% (25) | 41% | $1,862,838 |
| 2015 | 543 | 63 | 9% (48) | 44% | $1,318,853 |
| 2014 | 569 | 62 | 12% (70) | None | $889,475 |
| 2013 | 457 | 62 | 12% (54) | 38% | $918,414 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Tagrisso | 45 | $754,078 | $16,757 |
| Alecensa | 11 | $206,852 | $18,805 |
| Abiraterone Acetate | 63 | $198,092 | $3,144 |
| Sprycel | 12 | $195,361 | $16,280 |
| Xtandi | 14 | $184,129 | $13,152 |
| Votrient | 13 | $162,118 | $12,471 |
| Gilotrif | 14 | $149,507 | $10,679 |
| Posaconazole | 13 | $22,748 | $1,750 |
| Imatinib Mesylate | 20 | $8,029 | $401 |
| Eliquis | 11 | $6,749 | $614 |
| Aprepitant | 11 | $5,488 | $499 |
| Bicalutamide | 64 | $1,566 | $24 |
| Hydroxyurea | 29 | $778 | $27 |
| Anastrozole | 27 | $555 | $21 |
| Prednisone | 62 | $479 | $8 |
| Prochlorperazine Maleate | 32 | $458 | $14 |
| Acyclovir | 12 | $296 | $25 |
| Loperamide | 19 | $290 | $15 |
| Alendronate | 23 | $216 | $9 |
| Dexamethasone | 34 | $165 | $5 |
| Ondansetron | 26 | $69 | $3 |
2022: 23 drugs
| Tagrisso | 34 | $472,856 | $13,908 |
| Xtandi | 22 | $255,569 | $11,617 |
| Alecensa | 12 | $196,198 | $16,350 |
| Sprycel | 11 | $169,192 | $15,381 |
| Gilotrif | 14 | $142,522 | $10,180 |
| Votrient | 12 | $134,187 | $11,182 |
| Imbruvica | 12 | $123,406 | $10,284 |
| Posaconazole | 12 | $58,075 | $4,840 |
| Abiraterone Acetate | 24 | $51,209 | $2,134 |
| Venclexta | 11 | $30,639 | $2,785 |
| Eliquis | 11 | $6,285 | $571 |
| Bicalutamide | 70 | $1,147 | $16 |
| Hydroxyurea | 27 | $454 | $17 |
| Alendronate | 30 | $383 | $13 |
| Prednisone | 43 | $376 | $9 |
| Acyclovir | 14 | $346 | $25 |
| Anastrozole | 17 | $314 | $18 |
| Prochlorperazine Maleate | 14 | $232 | $17 |
| Dexamethasone | 28 | $208 | $7 |
| Hydrocodone-Acetaminophen | 18 | $174 | $10 |
| Ondansetron | 14 | $138 | $10 |
| Levofloxacin | 12 | $137 | $11 |
| Omeprazole | 13 | $59 | $5 |
2021: 18 drugs
| Tagrisso | 34 | $509,224 | $14,977 |
| Xtandi | 34 | $392,365 | $11,540 |
| Zytiga | 30 | $214,043 | $7,135 |
| Rozlytrek | 12 | $201,592 | $16,799 |
| Votrient | 11 | $157,350 | $14,305 |
| Gilotrif | 14 | $137,041 | $9,789 |
| Imbruvica | 14 | $134,055 | $9,575 |
| Abiraterone Acetate | 32 | $22,369 | $699 |
| Prednisone | 63 | $585 | $9 |
| Bicalutamide | 29 | $578 | $20 |
| Anastrozole | 18 | $554 | $31 |
| Hydroxyurea | 24 | $389 | $16 |
| Prochlorperazine Maleate | 19 | $333 | $18 |
| Alendronate | 33 | $155 | $5 |
| Gabapentin | 12 | $124 | $10 |
| Omeprazole | 18 | $121 | $7 |
| Dexamethasone | 15 | $101 | $7 |
| Ondansetron | 14 | $63 | $5 |
2020: 21 drugs
| Xtandi | 42 | $471,742 | $11,232 |
| Zytiga | 31 | $235,182 | $7,587 |
| Sprycel | 14 | $190,750 | $13,625 |
| Tagrisso | 12 | $179,977 | $14,998 |
| Lorbrena | 11 | $178,493 | $16,227 |
| Votrient | 13 | $174,142 | $13,396 |
| Ibrance | 11 | $146,529 | $13,321 |
| Venclexta | 12 | $128,022 | $10,669 |
| Gilotrif | 13 | $120,049 | $9,235 |
| Entecavir | 22 | $9,942 | $452 |
| Aprepitant | 14 | $7,292 | $521 |
| Prochlorperazine Maleate | 24 | $395 | $16 |
| Anastrozole | 16 | $394 | $25 |
| Prednisone | 41 | $338 | $8 |
| Bicalutamide | 26 | $327 | $13 |
| Hydroxyurea | 15 | $267 | $18 |
| Dexamethasone | 36 | $201 | $6 |
| Ondansetron | 20 | $196 | $10 |
| Alendronate | 36 | $193 | $5 |
| Hydrocodone-Acetaminophen | 14 | $100 | $7 |
| Omeprazole | 12 | $55 | $5 |
2019: 20 drugs
| Xtandi | 23 | $264,341 | $11,493 |
| Inlyta | 15 | $188,857 | $12,590 |
| Tagrisso | 12 | $184,856 | $15,405 |
| Votrient | 14 | $177,638 | $12,688 |
| Sprycel | 13 | $167,101 | $12,854 |
| Zytiga | 23 | $129,844 | $5,645 |
| Gilotrif | 13 | $111,158 | $8,551 |
| Tenofovir Disoproxil | 11 | $2,465 | $224 |
| Entecavir | 15 | $944 | $63 |
| Bicalutamide | 38 | $820 | $22 |
| Prochlorperazine Maleate | 42 | $466 | $11 |
| Hydroxyurea | 12 | $437 | $36 |
| Prednisone | 47 | $394 | $8 |
| Ondansetron | 39 | $318 | $8 |
| Gabapentin | 33 | $305 | $9 |
| Dexamethasone | 39 | $227 | $6 |
| Hydrocodone-Acetaminophen | 13 | $136 | $10 |
| Acyclovir | 11 | $88 | $8 |
| Alendronate | 13 | $84 | $6 |
| Omeprazole | 20 | $60 | $3 |
2018: 16 drugs
| Tagrisso | 25 | $383,519 | $15,341 |
| Xtandi | 30 | $328,414 | $10,947 |
| Zytiga | 32 | $326,960 | $10,217 |
| Tarceva | 23 | $174,886 | $7,604 |
| Sprycel | 12 | $145,517 | $12,126 |
| Ferriprox | 11 | $130,317 | $11,847 |
| Megestrol Acetate | 12 | $640 | $53 |
| Prednisone | 69 | $576 | $8 |
| Bicalutamide | 23 | $534 | $23 |
| Hydrocodone-Acetaminophen | 17 | $248 | $15 |
| Prochlorperazine Maleate | 35 | $233 | $7 |
| Ondansetron | 24 | $214 | $9 |
| Anastrozole | 14 | $173 | $12 |
| Dexamethasone | 18 | $161 | $9 |
| Gabapentin | 22 | $152 | $7 |
| Omeprazole | 29 | $123 | $4 |
2017: 19 drugs
| Zytiga | 41 | $363,350 | $8,862 |
| Xtandi | 23 | $234,632 | $10,201 |
| Votrient | 19 | $208,747 | $10,987 |
| Nexavar | 16 | $166,231 | $10,389 |
| Tarceva | 23 | $159,974 | $6,955 |
| Imatinib Mesylate | 14 | $116,333 | $8,310 |
| Procrit | 13 | $51,967 | $3,997 |
| Aprepitant | 13 | $6,553 | $504 |
| Enoxaparin | 11 | $6,438 | $585 |
| Hydroxyurea | 18 | $600 | $33 |
| Ondansetron | 43 | $466 | $11 |
| Prednisone | 46 | $383 | $8 |
| Anastrozole | 32 | $381 | $12 |
| Bicalutamide | 15 | $341 | $23 |
| Prochlorperazine Maleate | 47 | $263 | $6 |
| Omeprazole | 49 | $234 | $5 |
| Hydrocodone-Acetaminophen | 16 | $208 | $13 |
| Dexamethasone | 29 | $115 | $4 |
| Gabapentin | 12 | $78 | $6 |
2016: 18 drugs
| Votrient | 39 | $378,900 | $9,715 |
| Zytiga | 44 | $328,253 | $7,460 |
| Xtandi | 23 | $218,528 | $9,501 |
| Tarceva | 29 | $197,793 | $6,820 |
| Sprycel | 12 | $139,350 | $11,613 |
| Imatinib Mesylate | 11 | $94,280 | $8,571 |
| Neupogen | 23 | $38,893 | $1,691 |
| Exemestane | 12 | $7,413 | $618 |
| Hydroxyurea | 29 | $824 | $28 |
| Bicalutamide | 34 | $796 | $23 |
| Megestrol Acetate | 17 | $740 | $44 |
| Ondansetron | 28 | $598 | $21 |
| Anastrozole | 33 | $496 | $15 |
| Prednisone | 46 | $393 | $9 |
| Omeprazole | 53 | $231 | $4 |
| Hydrocodone-Acetaminophen | 12 | $222 | $19 |
| Prochlorperazine Maleate | 29 | $174 | $6 |
| Dexamethasone | 24 | $110 | $5 |
2015: 15 drugs
| Votrient | 41 | $295,035 | $7,196 |
| Zytiga | 42 | $271,708 | $6,469 |
| Tarceva | 37 | $243,446 | $6,580 |
| Inlyta | 17 | $175,292 | $10,311 |
| Thalomid | 13 | $104,623 | $8,048 |
| Neupogen | 25 | $65,681 | $2,627 |
| Enoxaparin | 21 | $11,843 | $564 |
| Anastrozole | 22 | $524 | $24 |
| Bicalutamide | 23 | $498 | $22 |
| Hydrocodone-Acetaminophen | 21 | $389 | $19 |
| Prednisone | 36 | $332 | $9 |
| Ondansetron | 18 | $230 | $13 |
| Prochlorperazine Maleate | 27 | $174 | $6 |
| Dexamethasone | 46 | $145 | $3 |
| Omeprazole | 26 | $134 | $5 |
2014: 18 drugs
| Votrient | 33 | $259,035 | $7,850 |
| Tarceva | 21 | $130,982 | $6,237 |
| Zytiga | 17 | $122,563 | $7,210 |
| Thalomid | 13 | $100,376 | $7,721 |
| Neupogen | 50 | $96,255 | $1,925 |
| Enoxaparin | 34 | $32,327 | $951 |
| Morphine Sulfate Er | 12 | $788 | $66 |
| Hydrocodone-Acetaminophen | 32 | $585 | $18 |
| Anastrozole | 21 | $572 | $27 |
| Oxycodone-Acetaminophen | 15 | $555 | $37 |
| Prochlorperazine Maleate | 51 | $378 | $7 |
| Bicalutamide | 12 | $318 | $26 |
| Ondansetron | 24 | $271 | $11 |
| Prednisone | 25 | $258 | $10 |
| Omeprazole | 37 | $240 | $6 |
| Dexamethasone | 76 | $221 | $3 |
| Gabapentin | 12 | $94 | $8 |
| Lorazepam | 12 | $26 | $2 |
2013: 14 drugs
| Votrient | 33 | $225,641 | $6,838 |
| Tarceva | 28 | $163,005 | $5,822 |
| Thalomid | 13 | $94,298 | $7,254 |
| Zytiga | 14 | $89,496 | $6,393 |
| Sutent | 13 | $71,922 | $5,532 |
| Bicalutamide | 22 | $2,224 | $101 |
| Megestrol Acetate | 18 | $1,330 | $74 |
| Anastrozole | 17 | $663 | $39 |
| Prochlorperazine Maleate | 56 | $345 | $6 |
| Hydrocodone-Acetaminophen | 27 | $336 | $12 |
| Ondansetron | 14 | $232 | $17 |
| Omeprazole | 20 | $199 | $10 |
| Prednisone | 23 | $131 | $6 |
| Dexamethasone | 24 | $71 | $3 |
Money from drug and device companies
$231 in 2025
| 2025 | 1 | 2 | None | $231 |
| 2022 | 2 | 3 | None | $50 |
| 2021 | 1 | 3 | None | $40 |
| 2019 | 3 | 3 | None | $63 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $231 | 2 payments
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Lynparza | $125 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Lynparza | $106 |
See earlier years (2022, 2021, 2019)
2022: $50
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
| Foundation Medicine | Foundationone | $24 | 1 payment
|
2021: $40
| Acrotech Biopharma | Beleodaq | $40 | 3 payments
|
2019: $63
| Exelixis | Cabometyx | $39 | 1 payment
|
| Seattle Genetics | Adcetris | $12 | 1 payment
|
| Pfizer | Ibrance | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1124114285
- Licence
- CA A83349California A83349: Current · expires 2028-09-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A833490
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2006-10-05
- NPI last updated
- 2007-09-12
This is when the NPI record was last certified, not a medical board exam.